Summary：Appili Therapeutics Unveils Strong FY 2026 Financials and Operational Milestones AchievedHALIFAX, No

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Appili Therapeutics Unveils Strong FY 2026 Financials and Operational Milestones Achieved

HALIFAX, Nova Scotia - Appili Therapeutics, a biopharmaceutical company focused on developing innovative treatments for infectious diseases, has announced its financial results for the fiscal year 2026, highlighting significant progress in its commercial and research endeavors. The company's robust performance is underscored by the growing commercial momentum of its flagship product, LIKMEZ (ATI-1501), in the U.S. market and notable advancements in its pipeline, supported by a substantial award from the National Institute of Allergy and Infectious Diseases (NIAID).

Key Developments
The fiscal year 2026 has been pivotal for Appili Therapeutics, marked by the continued commercial success of LIKMEZ, a medication designed to address a critical need in the treatment of certain infections. The product's uptake in the U.S. market has been encouraging, reflecting its value proposition to healthcare providers and patients alike. Furthermore, the company received a US$40 million award from the NIAID to support the advancement of VXV-01, its promising antiviral candidate, through Phase 1 clinical trials. This funding not only validates the potential of VXV-01 but also underscores the company's commitment to addressing pressing global health challenges.

Industry Analysis
Appili Therapeutics' achievements come at a time when the biopharmaceutical industry is increasingly focused on developing treatments for infectious diseases, driven by the ongoing need for effective countermeasures against emerging and re-emerging pathogens. The company's success in securing significant funding for VXV-01 highlights the importance of public-private partnerships in advancing medical research. Moreover, the commercial traction gained by LIKMEZ demonstrates the company's ability to navigate complex regulatory and market landscapes.

Future Outlook
Looking ahead, Appili Therapeutics is poised to continue its growth trajectory, driven by its diversified pipeline and the ongoing commercial success of LIKMEZ. The advancement of VXV-01 through Phase 1 trials is expected to yield critical data that could position the candidate for further development. The company's strong financial foundation, bolstered by the NIAID award and revenue from LIKMEZ, provides a solid platform for future investments in research and development.

Conclusion
Appili Therapeutics' fiscal year 2026 results are a testament to the company's strategic focus on developing and commercializing treatments for infectious diseases. With LIKMEZ gaining traction in the U.S. market and VXV-01 advancing through clinical trials, supported by significant funding from the NIAID, the company is well-positioned for continued success. As Appili Therapeutics looks to the future, its commitment to addressing the evolving landscape of infectious diseases is likely to remain a key driver of its growth and innovation.